The purpose of this study is to test if visualizing the heart with cardiac MRI/echo will be important in the understanding cardiac function and prediction of cardiopulmonary symptoms, physical effort tolerance, and outcomes in COVID-19 survivors. If successful, the research will allow us to identify the causes of lasting cardiopulmonary symptoms and begin developing cardiac and lung directed therapies accordingly.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Participants with focal fibrosis based on cardiac imaging (MRI and echocardiogram) > 3 months post-COVID-19 (coronavirus disease 2019) diagnosis, at first study visit
Timeframe: Day of first study visit, > 3 months post acute COVID-19 infection
Participants with focal fibrosis based on cardiac imaging (MRI and echocardiogram) at 12-36 months post first study visit
Timeframe: 12-36 months post first study visit
Blood oxygenation of participants at > 3 months post-COVID-19 diagnosis, first study visit
Timeframe: Day of first study visit, > 3 months post- acute COVID-19 infection
Blood oxygenation of participants at 12-36 months post first study visit
Timeframe: 12-36 months post first study visit
Lung abnormalities in participants at > 3 months post-COVID-19 infection
Timeframe: Day of first study visit, > 3 months post- acute COVID-19 infection
Lung abnormalities in participants at 12-36 months post first study visit
Timeframe: 12-36 months post first study visit
Quality of life (QOL) in participants at > 3 months post-COVID-19 diagnosis, at first study visit based on clinical indices and symptoms assessed by the (Patient-Reported Outcomes Measurement Information System) PROMIS-29 questionnaire.
Timeframe: Day of first study visit, > 3 months post- acute COVID-19 infection
Quality of life (QOL) in participants at 12-36 months post first study visit based on clinical indices and symptoms assessed by the (Patient-Reported Outcomes Measurement Information System) PROMIS-29 questionnaire.
Timeframe: 12-36 months post first study visit
Effort tolerance as measured by a 6-minute walk test at > 3 months post-COVID-19 diagnosis, at first study visit
Timeframe: Day of first study visit, > 3 months post- acute COVID-19 infection
Effort tolerance as measured by a 6-minute walk test at 12-36 months post first study visit
Timeframe: 12-36 months post first study visit
Participants with edema based on cardiac imaging (MRI and echocardiogram) at > 3 months post-COVID-19 diagnosis, at first study visit
Timeframe: Day of first study visit, > 3 months post- acute COVID-19 infection
Participants with edema based on cardiac imaging (MRI and echocardiogram) at 12-36 months post first study visit
Timeframe: 12-36 months post first study visit
Participants with diffuse fibrosis based on cardiac imaging (MRI and echocardiogram) at > 3 months post-COVID-19 diagnosis, at first study visit
Timeframe: Day of first study visit, > 3 months post- acute COVID-19 infection
Participants with diffuse fibrosis based on cardiac imaging (MRI and echocardiogram) at 12-36 months post first study visit
Timeframe: 12-36 months post first study visit
Quality of life (QOL) in participants at > 3 months post-COVID-19 diagnosis, at first study visit based on clinical indices and symptoms assessed by the Minnesota Living with Heart Failure Questionnaire (MLHFQ)
Timeframe: Day of first study visit, > 3 months post- acute COVID-19 infection
Quality of life (QOL) in participants based on clinical indices and symptoms assessed by the Seattle Angina (SAQ) questionnaire at 12-36 months post first study visit
Timeframe: 12-36 months post first study visit